Repeated-Dose High-Dose Ivermectin Pharmacokinetics and Safety in Children with Acute Dengue (PKIDEN) (2026)

Peer-Reviewed Study · Lapphra K, Mairiang D, Tarning J, Prayongkul D, Puttikhunt C, Songjaeng A, et al. (10 authors) · 2026

Lapphra K et al., 2026: Open-label dose-escalation pharmacokinetic and safety study of repeated-dose ivermectin (400 or 600 micrograms/kg daily for three days) in children aged 1-15 with acute dengue in Thailand.

Ivermectin has shown anti-dengue virus activity in experimental systems, and an adult dengue trial found faster clearance of circulating non-structural protein 1 (NS1) without improvement in viremia or clinical outcomes.

Lapphra K et al., 2026: Open-label dose-escalation pharmacokinetic and safety study of repeated-dose ivermectin (400 or 600 micrograms/kg daily for three days) in children aged 1-15 with acute dengue in Thailand. Prospective, open-label, sequential dose-escalation pharmacokinetic study, children 1-15 years weighing 15 kg or more, within 72 h of fever onset, Thailand; ivermectin 400 or 600 micrograms/kg once daily for 3 days; noncompartmental PK analysis with intensive sampling. The authors state the study 'was not designed to determine antiviral efficacy or clinical benefit'. Declarations: no competing interests. NCT03432442. Recorded because it is the paediatric dosing evidence behind any dengue use and it explicitly does not claim benefit. Study type: uncontrolled series.